CannapharmaRX Expands Cannabis Exports, Projects $1M+ Q3 Revenue

CannapharmaRX, Inc. (OTC PINK: CPMD), an emerging leader in global cannabis cultivation and exports, announces a series of strategic developments. The goal is to strengthen its international footprint and production capacity.

The company continues to make significant steps in its mission to supply premium cannabis products to high-demand international markets, including Germany, Portugal, and Israel. Here’s an overview of their recent shipments along with the Q3 revenue estimate.

Major Cannabis Shipments to Europe

Building on its successful export operations, CannapharmaRX has completed its second shipment to Germany in July by delivering 139.6 kilograms. Demand remains strong in Germany for our product, and we continue to take new orders for our strains.

In August, the company plans to execute two additional shipments to Germany and Portugal totaling 300 kilograms:

● 180.2 kg of high-THC products marking continued interest in our premium products.

● 119.8 kg of low-THC products for the more economical strains that we are producing.

Expanding Presence in Israel

In addition to its European exports, CannapharmaRX is also preparing a shipment of approximately 142 kg of medium-quality cannabis buds to Israel. This is another step in the company’s strategy to diversify its customer base and strengthen trade relationships in international markets. We are deliberately growing strains that cater to different consumers and different pricing needs so that we are scaling across all sectors.

Scaling Up Production with a New Growing Room

To meet increasing demand, CannapharmaRX plans to open its sixth growing room in September, bringing it closer to its total capacity of ten potential grow rooms. The expansion will also allow the company to cultivate new, recently tested cannabis varieties that have delivered promising results during trials.

Strong Q3 Revenue Forecast

The company projects third-quarter revenues of approximately $1,050,000 CAD, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.

CTO Update

CannapharmaRX continues to address regulatory matters in Canada with the BCSC. The company will submit a detailed response to the latest communication received in May by the end of August, with legal guidance from Fasken Law Firm.

Cautionary Note Regarding Forward-Looking Information or Statements

This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are ‘forward-looking information or statements.’ Forward-looking information or statements can be identified by the use of words such as ‘plans,’ ‘expects,’ or ‘does not expect,’ ‘is expected,’ ‘estimates,’ ‘intends,’ ‘anticipates,’ or ‘does not anticipate,’ or ‘believes,’ or variations of such words and phrases or statements that certain actions, events or results ‘may,’ ‘could,’ ‘would,’ ‘might’ or ‘will’ be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.

View the original press release on accesswire.com